Search
Last chance: special EAPM2017 registration offer for EHA members
EAMP2017 will take place in Belfast, Ireland, from 27-29 November 2017. The European Alliance for Personalised Medicine (EAPM), launched in March 2012, brings together European healthcare experts and patient advocates involved with major chronic diseases.
Read moreHARMONY Alliance: 2nd General Assembly, October 23-24, 2017
The 2nd HARMONY General Assembly is organised from 23-24 October 2017 at Bayer in Berlin. The HARMONY Alliance is a European Network of Excellence for Big Data in Hematology, consisting of 51 partners.
Read moreLymphoid malignancies dissected in Warsaw
The EHA–PTHiT Tutorial on Lymphoid Malignancies was held on March 17-18, 2017 in Warsaw, Poland. 96% of meeting attendees were satisfied with the tutorial saying that their expectations are met.
Read moreHARMONY: Better care of patients with hematologic malignancies kicked off!
“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”, said Jesús María Hernandez Rivas, Project…
Read moreYoung researchers to benefit from EHA training and mentoring
Participation in EHA-CRTH will allow these researchers to fine-tune the skills and knowledge required to successfully design, run and complete clinical trials.
Read morePress Release: Economic burden of blood disorders in EU is €23 billion
The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreKiller antibodies against AML
Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.
Read moreImproved survival for adult Acute Lymphoblastic Leukemia (ALL) patients
Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.
Read moreThe Clot Thickens
Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).
Read more